FORT MILL, SC / ACCESSWIRE / October 15, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 15^th International Symposium on Catheter Ablation Techniques (ISCAT) from October 16 - 18 in Paris, France.

ISCAT is a biannual European meeting that focuses on new and emerging catheter ablation technologies, techniques, and study data for both atrial and ventricular arrhythmias.

"Attending meetings is a crucial part of our sales strategy," said David Jenkins, CEO of Catheter Precision. "Meetings allow us the chance to meet with physicians in a dedicated, focused setting and showcase our technologies while generating new sales leads. In this case, we will demonstrate VIVO and highlight our newest clinical data, demonstrating the value and accuracy of VIVO, that was presented in September at the European Society of Cardiology meeting."

About VIVO

Catheter Precision's VIVO? (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's Form 10-K filed with the SEC and available at www.sec.gov.